Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRITON2 phase 2 study of rucaparib in metastatic castration-resistant prostate cancer with homologous recombination deficiency
MOH_2017-06-13_000518Phase 2Completed
- Sponsor
- Clovis Oncology
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rucaparib in metastatic castration-resistant prostate cancer (mCRPC) and castration-resistant prostate cancer (CRPC), sponsored by Clovis Oncology. Started Oct 2017; status: completed.
02
Drugs
rucaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on MOH_2017-06-13_000518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-13_000518.